Monday, October 15, 2012
Longitude Capital has closed a
second fund that will focus on de-risked investment opportunities in biotech
and medtech, a strategy the firm said was successful enough for its first fund
to lure back existing LPs.
The oversubscribed Longitude
Venture Partners II closed last week at $385 million, eclipsing the $325
million that was both the second fund's initial target and the size of the 2008
fund LVP I.